Aurobindo Pharma announced that its subsidiary, CuraTeQ Biologics s.r.o., has received marketing authorization from the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) for Bevqolva, ...

GSK’s FIRST-ENGOT-OV44 phase III clinical trial of Zejula and Jemperl in first line advanced ovarian cancer meets primary endpoint: London Saturday, December 21, 2024, 09:00 Hrs ...

LONDON, UK I, 2024 I GSK plc (LSE/NYSE: GSK) today announced headline results from the FIRST-ENGOT-OV44 phase III trial evaluating Zejula ...

From reprogrammed stem cells to next-generation gene editing, 2024 has seen some incredible developments with the potential to become new treatments.

Company aligned with FDA on CMC strategy and requirements in preparation of Phase 3 pivotal trial of IMNN-001 Vertical integration of major components assures a high-quality, commercially viable futur ...

Company aligned with FDA on CMC strategy and requirements in preparation of Phase 3 pivotal trial of IMNN-001Vertical integration of major ...

This paper presents the important discovery that lipid metabolic imbalance caused by Snail, an EMT-related transcription factor, contributes to the acquisition of chemoresistance in cancer cells.

Merck's strong financial performance in oncology and vaccines drove a 9% sales increase earlier in Q1 of 2024. See why I rate ...

The results come two months after Merck shared positive results from the phase 3 KEYNOTE-689 trial of Keytruda as a ...

The complex interactions of the tumor–immune–gut axis can shape responses to immunotherapy in ovarian cancer, emphasizing the ...

Study analyzed global patterns and trends in ovarian cancer incidence from 1988 to 2017, highlighting variations by ...

Recent research has highlighted significant disparities in ovarian cancer survival rates within AANHPI communities, ...